Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

8.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
The Thyroid Gland01:23

The Thyroid Gland

7.9K
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
7.9K
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

5.8K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
5.8K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

86.8K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.8K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

10.1K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Biomarker Signature of Relapse in Neuromyelitis Optica Spectrum Disorders in the CIRCLES Observational Study.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same author

Management of Thyroid Eye Disease: A Comparison Between Three Recent Clinical Guidelines.

Ophthalmology and therapy·2026
Same author

Thyroid Eye Disease (TED) Monocytes Express a Functional Thyrotropin Receptor and Express Increased IL-6 and IL-8: Possible Mechanistic Implications.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Approach to the patient: therapeutic mitigation of lacrimal manifestations in thyroid eye disease.

The Journal of clinical endocrinology and metabolism·2026
Same author

SPHERES: innovative registry addressing the new era of neuromyelitis optica spectrum disorders (NMOSD) therapy.

Multiple sclerosis and related disorders·2025

Related Experiment Video

Updated: Feb 16, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.5K

IGF1 receptor and thyroid-associated ophthalmopathy.

Michelle Mohyi1, Terry J Smith2,3

  • 1Department of Ophthalmology and Visual SciencesUniversity of Michigan, Ann Arbor, Michigan, USA.

Journal of Molecular Endocrinology
|December 24, 2017
PubMed
Summary

Thyroid-associated ophthalmopathy (TAO) involves eye inflammation and remodeling. Targeting the insulin-like growth factor I receptor (IGF1R) shows promise for treating active TAO and potentially other autoimmune diseases.

Keywords:
IGF receptorimmune systemsignal transductionthyroid

More Related Videos

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.1K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K

Related Experiment Videos

Last Updated: Feb 16, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.5K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.1K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Immunology

Background:

  • Thyroid-associated ophthalmopathy (TAO) is an autoimmune condition affecting eye tissues, often linked to Graves' disease.
  • Current treatments for TAO are limited due to its unclear pathogenesis.
  • The thyrotropin receptor (TSHR) is implicated in Graves' disease, but its role in TAO is less understood.

Purpose of the Study:

  • To investigate the role of the insulin-like growth factor I receptor (IGF1R) in TAO pathogenesis.
  • To explore the potential of targeting IGF1R as a therapeutic strategy for TAO.

Main Methods:

  • Detection of activating antibodies against IGF1R in patients with Graves' disease.
  • Analysis of IGF1R signaling in patient-derived orbital fibroblasts.
  • Investigation of the functional and physical interaction between TSHR and IGF1R.
  • Assessment of IGF1R inhibition on receptor signaling.

Main Results:

  • Activating antibodies against IGF1R were found in patients with Graves' disease.
  • IGF1R signaling was initiated in orbital fibroblasts by these antibodies.
  • A functional and physical interaction between TSHR and IGF1R was identified.
  • Inhibiting IGF1R activity attenuated signaling from both TSHR and IGF1R.

Conclusions:

  • Targeting IGF1R is a rational therapeutic strategy for active TAO.
  • A clinical trial of teprotumumab, an IGF1R inhibitor, demonstrated potential effectiveness and safety in moderate to severe active TAO.
  • This therapeutic approach may benefit other autoimmune diseases.